Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Payables (2019 - 2024)

Benitec Biopharma's Payables history spans 7 years, with the latest figure at $6.3 million for Q1 2025.

  • For Q1 2025, Payables changed N/A year-over-year to $6.3 million; the TTM value through Mar 2025 reached $6.3 million, changed N/A, while the annual FY2024 figure was $4.2 million, 28.91% up from the prior year.
  • Payables for Q1 2025 was $6.3 million at Benitec Biopharma, up from $2.4 million in the prior quarter.
  • Across five years, Payables topped out at $6.3 million in Q1 2025 and bottomed at $880000.0 in Q2 2021.
  • The 5-year median for Payables is $2.4 million (2022), against an average of $2.8 million.
  • The largest annual shift saw Payables skyrocketed 448.17% in 2021 before it plummeted 51.08% in 2024.
  • A 5-year view of Payables shows it stood at $1.9 million in 2021, then dropped by 5.96% to $1.8 million in 2022, then surged by 169.78% to $4.9 million in 2023, then tumbled by 51.08% to $2.4 million in 2024, then soared by 158.96% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Payables are $6.3 million (Q1 2025), $2.4 million (Q4 2024), and $3.8 million (Q3 2024).